Cargando…

Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics

The FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) gene mutation is present in ~20% of patients with de novo acute myeloid leukemia (AML). Patients with an FLT3-ITD mutation have a poor prognosis. However, the prognostic function of FLT3-ITD combined with other cytogenetic abnorma...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Shandong, Wang, Chunling, Chen, Yue, Deng, Yuan, Song, Lixiao, Shi, Yuyue, Ling, Lanlan, Ding, Banghe, He, Zhengmei, Yu, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876342/
https://www.ncbi.nlm.nih.gov/pubmed/31807186
http://dx.doi.org/10.3892/ol.2019.11051
_version_ 1783473191979581440
author Tao, Shandong
Wang, Chunling
Chen, Yue
Deng, Yuan
Song, Lixiao
Shi, Yuyue
Ling, Lanlan
Ding, Banghe
He, Zhengmei
Yu, Liang
author_facet Tao, Shandong
Wang, Chunling
Chen, Yue
Deng, Yuan
Song, Lixiao
Shi, Yuyue
Ling, Lanlan
Ding, Banghe
He, Zhengmei
Yu, Liang
author_sort Tao, Shandong
collection PubMed
description The FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) gene mutation is present in ~20% of patients with de novo acute myeloid leukemia (AML). Patients with an FLT3-ITD mutation have a poor prognosis. However, the prognostic function of FLT3-ITD combined with other cytogenetic abnormalities are not clear. In the present study, a retrospective analysis of 103 newly diagnosed patients with AML was performed. The results revealed that the overall survival (OS) and recurrence-free survival (RFS) times were significantly longer in patients with an FLT3-ITD mutation combined with other favorable risk genes, compared with in those patients with a single FLT3-ITD mutation (P=0.0361 and P=0.0426). Sorafenib combined with chemotherapy significantly improved the overall response rate (ORR) when compared with mono-chemotherapy (P=0.039), but no significant differences were observed in the OS and RFS. In conclusion, favorable-risk cytogenetics may improve the clinical outcomes of patients with FLT3-ITD-mutated AML, but adverse-risk cytogenetics may not further worsen the prognosis. Sorafenib combined with chemotherapy may increase the ORR but would not result in a longer OS and RFS.
format Online
Article
Text
id pubmed-6876342
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-68763422019-12-05 Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics Tao, Shandong Wang, Chunling Chen, Yue Deng, Yuan Song, Lixiao Shi, Yuyue Ling, Lanlan Ding, Banghe He, Zhengmei Yu, Liang Oncol Lett Articles The FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) gene mutation is present in ~20% of patients with de novo acute myeloid leukemia (AML). Patients with an FLT3-ITD mutation have a poor prognosis. However, the prognostic function of FLT3-ITD combined with other cytogenetic abnormalities are not clear. In the present study, a retrospective analysis of 103 newly diagnosed patients with AML was performed. The results revealed that the overall survival (OS) and recurrence-free survival (RFS) times were significantly longer in patients with an FLT3-ITD mutation combined with other favorable risk genes, compared with in those patients with a single FLT3-ITD mutation (P=0.0361 and P=0.0426). Sorafenib combined with chemotherapy significantly improved the overall response rate (ORR) when compared with mono-chemotherapy (P=0.039), but no significant differences were observed in the OS and RFS. In conclusion, favorable-risk cytogenetics may improve the clinical outcomes of patients with FLT3-ITD-mutated AML, but adverse-risk cytogenetics may not further worsen the prognosis. Sorafenib combined with chemotherapy may increase the ORR but would not result in a longer OS and RFS. D.A. Spandidos 2019-12 2019-11-05 /pmc/articles/PMC6876342/ /pubmed/31807186 http://dx.doi.org/10.3892/ol.2019.11051 Text en Copyright: © Tao et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Tao, Shandong
Wang, Chunling
Chen, Yue
Deng, Yuan
Song, Lixiao
Shi, Yuyue
Ling, Lanlan
Ding, Banghe
He, Zhengmei
Yu, Liang
Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics
title Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics
title_full Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics
title_fullStr Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics
title_full_unstemmed Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics
title_short Prognosis and outcome of patients with acute myeloid leukemia based on FLT3-ITD mutation with or without additional abnormal cytogenetics
title_sort prognosis and outcome of patients with acute myeloid leukemia based on flt3-itd mutation with or without additional abnormal cytogenetics
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876342/
https://www.ncbi.nlm.nih.gov/pubmed/31807186
http://dx.doi.org/10.3892/ol.2019.11051
work_keys_str_mv AT taoshandong prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics
AT wangchunling prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics
AT chenyue prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics
AT dengyuan prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics
AT songlixiao prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics
AT shiyuyue prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics
AT linglanlan prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics
AT dingbanghe prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics
AT hezhengmei prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics
AT yuliang prognosisandoutcomeofpatientswithacutemyeloidleukemiabasedonflt3itdmutationwithorwithoutadditionalabnormalcytogenetics